stockrowViking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) Return on equity
Viking Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was −96.4%, down 49.0 percentage points from fiscal 2025 (−47.3%). Over the past ten years it has ranged from −191.4% (fiscal 2017) to 349.2% (fiscal 2015); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −47.3% | (29.44) |
| FY2024 | −17.9% | 16.89 |
| FY2023 | −34.8% | 4.88 |
| FY2022 | −39.7% | (15.02) |
| FY2021 | −24.7% | (9.50) |
| FY2020 | −15.2% | (6.18) |
| FY2019 | −8.97% | 5.21 |
| FY2018 | −14.2% | 177.18 |
| FY2017 | −191.4% | (15.65) |
| FY2016 | −175.7% | (524.93) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.3% |
| IRON Disc Medicine, Inc. compare | −39.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −43.6% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. | −96.4% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −319.8% |
| CELC Celcuity, Inc. compare | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)